Next Article in Journal
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma
Next Article in Special Issue
How Morphology Shapes Survival in Invasive Squamous Cell Carcinoma of the Lung
Previous Article in Journal
Radial Artery Spasm—A Review on Incidence, Prevention and Treatment
Previous Article in Special Issue
Pelvic Exenteration in Advanced, Recurrent or Synchronous Cancers—Last Resort or Therapeutic Option?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 14
Issue 17
10.3390/diagnostics14171898
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib

by
Vlad-Adrian Afrăsânie
1,2,†,
Alexandra Rusu
1,†,
Adelina Silvana Gheorghe
3,4,*,
Eliza Maria Froicu
1,
Elena Adriana Dumitrescu
3,
Bogdan Gafton
1,2,
Teodora Alexa-Stratulat
1,2,
Lucian Miron
1,2,
Dana Lucia Stănculeanu
3,4 and
Mihai Vasile Marinca
1,2
1
Department of Medical Oncology, Regional Institute of Oncology, 700483 Iasi, Romania
2
Department of Oncology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
3
Department of Oncology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
4
Department of Medical Oncology I, Institute of Oncology “Prof. Dr. Al. Trestioreanu” Bucharest, 022328 Bucharest, Romania
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2024, 14(17), 1898; https://doi.org/10.3390/diagnostics14171898
Submission received: 19 July 2024 / Revised: 16 August 2024 / Accepted: 23 August 2024 / Published: 29 August 2024
(This article belongs to the Special Issue Contemporary Challenges and Innovations in Oncological Diagnosis and Treatment: The Romanian Landscape)
Browse Figures
Review Reports Versions Notes

Abstract

Ovarian cancer is one of the most frequent malignancies in women. The treatment landscape underwent significant changes as new agents were introduced in ovarian cancer management over the last decade. We present two cases of long responses to Olaparib in BRCA (BReast CAncer gene) mutant ovarian cancer patients. The first case belongs to a 42-year-old female diagnosed with advanced ovarian carcinoma with a rare germinal mutation (BRCA1 c.68_69delAG, commonly found in descendants of Ashkenazi Jewish populations, but also Arabic and Asian ones) and a significant family history of ovarian and breast cancers. After poorly tolerated neoadjuvant chemotherapy, the patient underwent total hysterectomy, bilateral adnexectomy, and intraperitoneal hyperthermic chemotherapy. After eight months, the disease progressed, and first-line platinum chemotherapy was administered. Although not well-tolerated (grade 3 anemia, allergic reactions), chemotherapy resulted in a partial response, and given the patient’s characteristics, maintenance with Olaparib was recommended. Treatment is ongoing (total current duration 69 months) and tolerated well (grade 1 side effects). This case illustrates the long-term benefits that novel therapies like Olaparib may offer in patients with platinum-sensitive relapsed ovarian cancer harboring a rare BRCA mutation. The second case highlights a 55-year-old postmenopausal woman diagnosed with ovarian cancer, FIGO stage IVA. Initial treatment included six cycles of chemotherapy, which led to a partial response, followed by interval debulking surgery and another four cycles of chemotherapy. Subsequent Olaparib maintenance therapy post BRCA1 mutation identification contributed to a significant progression-free survival of 65 months until disease recurrence and secondary cytoreductive surgery, showcasing the effectiveness of PARP inhibitors in personalized oncology treatment of ovarian cancer.
Keywords: BRCA1 mutation; ovarian cancer; Olaparib; chemotherapy BRCA1 mutation; ovarian cancer; Olaparib; chemotherapy

Share and Cite

MDPI and ACS Style

Afrăsânie, V.-A.; Rusu, A.; Gheorghe, A.S.; Froicu, E.M.; Dumitrescu, E.A.; Gafton, B.; Alexa-Stratulat, T.; Miron, L.; Stănculeanu, D.L.; Marinca, M.V. Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib. Diagnostics 2024, 14, 1898. https://doi.org/10.3390/diagnostics14171898

AMA Style

Afrăsânie V-A, Rusu A, Gheorghe AS, Froicu EM, Dumitrescu EA, Gafton B, Alexa-Stratulat T, Miron L, Stănculeanu DL, Marinca MV. Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib. Diagnostics. 2024; 14(17):1898. https://doi.org/10.3390/diagnostics14171898

Chicago/Turabian Style

Afrăsânie, Vlad-Adrian, Alexandra Rusu, Adelina Silvana Gheorghe, Eliza Maria Froicu, Elena Adriana Dumitrescu, Bogdan Gafton, Teodora Alexa-Stratulat, Lucian Miron, Dana Lucia Stănculeanu, and Mihai Vasile Marinca. 2024. "Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib" Diagnostics 14, no. 17: 1898. https://doi.org/10.3390/diagnostics14171898

APA Style

Afrăsânie, V.-A., Rusu, A., Gheorghe, A. S., Froicu, E. M., Dumitrescu, E. A., Gafton, B., Alexa-Stratulat, T., Miron, L., Stănculeanu, D. L., & Marinca, M. V. (2024). Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib. Diagnostics, 14(17), 1898. https://doi.org/10.3390/diagnostics14171898

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop